prostate cancer Archives

Developments

Health Canada approves Profound Medical’s TULSA-PRO system

Health Canada approved the sale of Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO system for the ablation of low-to intermediate-risk organ-confined prostate cancer. TULSA-PRO is a transurethral prostate tissue...

November 25, 2019

Developments

Study finds invasive prostate cancer incidence rising among young men

The incidence of prostate cancer among adolescents and young adults has increased in the U.S. and many other countries during the past three decades, in direct contrast to older men, according to study results published...

November 20, 2019

Developments

Profound Medical gets FDA clearance to market TULSA-PRO for the treatment of prostate disease

Profound Medical (TSX:PRN; OTCQX:PRFMF) received FDA clearance to market TULSA-PRO for the ablation of prostate tissue, with an FDA label allowing U.S. surgeons to perform procedures on both malignant and benign tissue...

August 16, 2019

Feature

Soricimed planning to initiate Phase 1b/2a solid tumor trial in Q2

Closely-held Soricimed Biopharma expects to initiate in the second quarter of 2018 a Phase 1b/2a clinical trial with its SOR-C13 drug candidate in patients with prostate cancer, including men who have failed first line...

December 12, 2017

Feature

Profound makes leap to platform company from prostate product

Arun Menawat, CEO With its recent acquisition of Royal Philips’ (NYSE:PHG; AEX:PHIA) Sonalleve business, Profound Medical (OTCQX:PRFMF; TSXV:PRN) is making the leap from a medical device company focused on prostate...

September 5, 2017

Feature

Profound Medical’s TULSA-PRO pilot OUS launch: paving the way for global growth

After nearly a decade of R&D, Profound Medical (OTCQX:PRFMF; TSXV:PRN) is now conducting a pilot launch of its TULSA-PRO medical device to ablate tissue in localized prostate cancer within key European and other CE...

March 28, 2017

Feature

3D Signatures seeking partners for genomic imaging platform

3D Signatures (TSX-V:DXD) which has developed proprietary software with the potential to analyze a patient’s chromosomal arrangement, or signature, is seeking collaborations to advance its TeloView platform in the areas...

November 29, 2016

Feature

ESSA Pharma takes unique approach to prostate cancer

A marine sponge, Geodia lindgreni, native to Papua New Guinea may hold the key to a new approach in the treatment of prostrate cancer by ESSA Pharma (NASDAQ:EPIX; TSX:EPI). “Our scientific founders from the BC Cancer...

June 7, 2016

Feature

OncoGenex’s OGX-427 drug gaining investor attention

Even though OncoGenex Pharmaceuticals (NASDAQ:OGXI) and its pivotal programs with lead oncology candidate, custirsen, are being closely followed, investors are beginning to notice the company’s second generation...

March 26, 2013

Tag - prostate cancer

Health Canada approves Profound Medical’s TULSA-PRO system

Study finds invasive prostate cancer incidence rising among young men

Profound Medical gets FDA clearance to market TULSA-PRO for the treatment of prostate disease

Soricimed planning to initiate Phase 1b/2a solid tumor trial in Q2

Profound makes leap to platform company from prostate product

Profound Medical’s TULSA-PRO pilot OUS launch: paving the way for global growth

3D Signatures seeking partners for genomic imaging platform

ESSA Pharma takes unique approach to prostate cancer

OncoGenex’s OGX-427 drug gaining investor attention

General

More